"Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Descriptor ID |
D009369
|
MeSH Number(s) |
C04
|
Concept/Terms |
Neoplasms- Neoplasms
- Neoplasia
- Neoplasias
- Neoplasm
- Tumors
- Tumor
Cancer- Cancer
- Cancers
- Malignant Neoplasms
- Malignant Neoplasm
- Neoplasm, Malignant
- Neoplasms, Malignant
- Malignancy
- Malignancies
Benign Neoplasms- Benign Neoplasms
- Neoplasms, Benign
- Benign Neoplasm
- Neoplasm, Benign
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms".
This graph shows the total number of publications written about "Neoplasms" by people in this website by year, and whether "Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 17 | 3 | 20 |
1996 | 14 | 6 | 20 |
1997 | 15 | 9 | 24 |
1998 | 14 | 3 | 17 |
1999 | 12 | 2 | 14 |
2000 | 17 | 5 | 22 |
2001 | 21 | 5 | 26 |
2002 | 26 | 9 | 35 |
2003 | 35 | 11 | 46 |
2004 | 47 | 14 | 61 |
2005 | 34 | 12 | 46 |
2006 | 36 | 11 | 47 |
2007 | 52 | 14 | 66 |
2008 | 49 | 13 | 62 |
2009 | 43 | 11 | 54 |
2010 | 49 | 6 | 55 |
2011 | 59 | 14 | 73 |
2012 | 69 | 9 | 78 |
2013 | 64 | 15 | 79 |
2014 | 89 | 17 | 106 |
2015 | 107 | 9 | 116 |
2016 | 79 | 22 | 101 |
2017 | 91 | 12 | 103 |
2018 | 86 | 9 | 95 |
2019 | 107 | 17 | 124 |
2020 | 135 | 12 | 147 |
2021 | 128 | 7 | 135 |
2022 | 119 | 0 | 119 |
2023 | 112 | 3 | 115 |
2024 | 63 | 29 | 92 |
2025 | 7 | 1 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasms" by people in Profiles.
-
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2025 Apr 01; 31(7):1233-1242.
-
Young People with Cancer: A Growing Population in Need of United Attention. Curr Oncol Rep. 2025 Apr; 27(4):333-335.
-
Trends in complexity of single-agent and combination therapies for solid tumor cancers approved by the US Food and Drug Administration. Oncologist. 2025 Mar 10; 30(3).
-
Design and analysis considerations for investigating patient subgroups of interest within cancer clinical trials. J Natl Cancer Inst Monogr. 2025 Mar 01; 2025(68):22-29.
-
N6-methyladenosine reader YTHDF2 in cell state transition and antitumor immunity. RNA. 2025 Feb 19; 31(3):395-401.
-
Microbiota does not influence tumor development in two models of heritable cancer. mBio. 2025 Mar 12; 16(3):e0386624.
-
Pediatric DTC Genetic Testing for Adult-Onset Inherited Cancer Risk: The Perspectives of High-Risk Parents. Public Health Genomics. 2025; 28(1):102-112.
-
Cancer Risk and Estimated Lithium Exposure in Drinking Groundwater in the US. JAMA Netw Open. 2025 Feb 03; 8(2):e2460854.
-
Childhood Cancer-Connect: Identifying solutions to elevating the cancer experience for adolescents and young adults with cancer. J Natl Cancer Inst. 2025 Feb 01; 117(2):229-239.
-
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product. Nat Commun. 2025 Jan 02; 16(1):32.